- Home
- GLOB vs BLCO Comparison
GLOB vs BLCO Comparison
Compare GLOB & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLOB
- BLCO
- Stock Information
- Founded
- GLOB 2003
- BLCO 1853
- Country
- GLOB Luxembourg
- BLCO Canada
- Employees
- GLOB N/A
- BLCO N/A
- Industry
- GLOB EDP Services
- BLCO Ophthalmic Goods
- Sector
- GLOB Technology
- BLCO Health Care
- Exchange
- GLOB Nasdaq
- BLCO Nasdaq
- Market Cap
- GLOB 4.7B
- BLCO 4.9B
- IPO Year
- GLOB 2014
- BLCO 2022
- Fundamental
- Price
- GLOB $74.10
- BLCO $13.70
- Analyst Decision
- GLOB Buy
- BLCO Hold
- Analyst Count
- GLOB 15
- BLCO 11
- Target Price
- GLOB $162.07
- BLCO $15.80
- AVG Volume (30 Days)
- GLOB 1.5M
- BLCO 1.0M
- Earning Date
- GLOB 08-14-2025
- BLCO 07-30-2025
- Dividend Yield
- GLOB N/A
- BLCO N/A
- EPS Growth
- GLOB N/A
- BLCO N/A
- EPS
- GLOB 3.38
- BLCO N/A
- Revenue
- GLOB $2,455,696,000.00
- BLCO $4,891,000,000.00
- Revenue This Year
- GLOB $4.36
- BLCO $7.10
- Revenue Next Year
- GLOB $5.91
- BLCO $5.50
- P/E Ratio
- GLOB $22.10
- BLCO N/A
- Revenue Growth
- GLOB 11.90
- BLCO 8.81
- 52 Week Low
- GLOB $74.15
- BLCO $10.45
- 52 Week High
- GLOB $238.32
- BLCO $21.69
- Technical
- Relative Strength Index (RSI)
- GLOB 32.35
- BLCO 48.85
- Support Level
- GLOB $74.15
- BLCO $13.60
- Resistance Level
- GLOB $82.71
- BLCO $15.00
- Average True Range (ATR)
- GLOB 3.37
- BLCO 0.60
- MACD
- GLOB -0.97
- BLCO -0.11
- Stochastic Oscillator
- GLOB 7.75
- BLCO 27.21
About GLOB Globant S.A.
Globant is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2003 in Argentina but is currently headquartered in Luxembourg and primarily serves clients in the US and Latin America. Globant's client base is relatively concentrated in the media and entertainment and financial services industries.
About BLCO Bausch + Lomb Corporation
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.